A team of researchers at The University of Texas MD Anderson Cancer Center have identified two cancer-promoting pathways in esophageal cancer.
The discovery indicates that these pathways are crucial in the development of esophageal cancer development and progression of the disease. These groundbreaking findings can lead to advanced therapy for esophageal cancer which is already developed.
A combination of two FDA approved drugs which are used in other types of cancer have been shown to “steeply reduced the tumor burden in a mouse model of esophageal adenocarcinoma,” stated Mien-Chie Hung, Ph.D.
“Esophageal cancer is one of the most aggressive forms of cancer, with fewer than 20 percent of patients surviving for five years, the study notes. And it has become more frequent in the United States by 5 to 10 percent annually since the 1980s. Inflammation and obesity are thought to be driving factors in this increased incidence”, Hung said.
The team of researchers conducted experiments with cell lines, mouse models and actual human tumor samples.
To read the full story released by The University of Texas MD Anderson Cancer Center, click here.
The Salgi Esophageal Cancer Research Foundation 